Osimertinib in Untreated EGFR -Mutated Advanced Non–Small ...
2017年11月18日 · The results of the FLAURA trial show that in patients with previously untreated EGFR mutation–positive advanced NSCLC, osimertinib treatment resulted in significantly …
Overall Survival with Osimertinib in Untreated, EGFR-Mutated ...
2019年11月21日 · In the FLAURA trial, a double-blind, randomized phase 3 trial involving untreated patients with EGFR mutation–positive advanced NSCLC, those who received …
Osimertinib with or without Chemotherapy in EGFR -Mutated ...
2023年11月8日 · Osimertinib is a third-generation epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …
Osimertinib with or without Chemotherapy in EGFR-Mutated ...
2023年11月8日 · Conclusions: First-line treatment with osimertinib-chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients …
FDA approves osimertinib with chemotherapy for EGFR-mutated ...
On February 16, 2024, the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) with platinum-based chemotherapy for patients with locally …
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell ...
2018年1月11日 · Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and …
Osimertinib in Advanced Lung Cancer with EGFR Mutations
2019年12月12日 · The cancer drug osimertinib (Tagrisso) improves survival in people with non-small cell lung cancer with EGFR mutations, updated results from the FLAURA clinical trial …
FLAURA2 Results Demonstrate Osimertinib Plus ... - IASLC
According to Dr. Jänne, The FLAURA2 trial builds on the favorable results observed in the phase III FLAURA trial, where osimertinib displayed superiority over comparator EGFR-TKIs. The …
Final FLAURA Results Demonstrate Overall Survival Benefit
2019年9月29日 · First-line treatment with osimertinib provided improved overall survival (OS) over standard treatment with a comparator tyrosine kinase inhibitor (TKI) in patients with epidermal …
FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves ...
2023年10月10日 · FLAURA2 was designed to evaluate whether osimertinib plus standard platinum-based chemotherapy would lead to superior outcomes compared with osimertinib …
- 某些结果已被删除